Abstract:Objective To explore the clinical effect of using Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor in the treatment of patients with diabetic skin difficult-to-heal ulcers. Methods Seventy-eight patients with diabetic skin difficult-to-heal ulcers treated in this hospital from February 2018 to February 2020 were included as study subjects, and the patients were randomly divided into the conventional group and the observation group, each with 39 cases, and the depth of trauma was deep second degree according to the random number table method. Patients in the conventional group were treated with Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment), and patients in the observation group were treated with Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor. The treatment conditions (clinical indexes, ulcer healing, treatment efficiency) of the two groups were analyzed and compared. Results The treatment efficiency of the observation group was 97.44%, which was significantly higher than that of the conventional group, and the difference was statistically significant (χ~2=7.341,P=0.007); the area of ulceration, the quality of life score, the fasting glucose, the 2 h postprandial glucose level, the rate of ulceration healing, the average time of expectoration of the decay, the average time of muscle growth, the average healing time, and the number of medication changes of the observation group were respectively (3.54±1.76) cm2, (82.98±10.62) points, (4.25±0.73) mmol/L, (5.36±1.62) mmol/L, (60.13±2.14)%, (13.84±4.80) d, (15.15±7.03) d, (26.66±7.28) d, and (18.82±3.80) times respectively, which were significantly better than the conventional group, and the difference was statistically significant (t=8.830, 8.138, 10.706, 8.246, 82.288, 8.462, 10.623, 8.307, 8.693,P<0.001). Conclusion The use of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor for the treatment of patients with diabetic cutaneous refractory ulcers can improve the patients' blood glucose level, and can enhance the patients' quality of life, and the patients' ulcers are in good condition of healing, with a high clinical application value.
Yan Xiaohang. Effect analysis of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor in the treatment of diabetic skin ulcers[J]. Diabetes New World, 2022, 25 (01): 1-4.